C. Thoma

发表

Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.

S. Kehoe, L. Seymour, N. Green, 2008, Human gene therapy.

Kidney cancer: When worlds collide — integrating metabolic and transcriptomic data in ccRCC

C. Thoma, 2016, Nature Reviews Urology.

Prostate cancer: A step to identifying men at high risk of metastatic disease

C. Thoma, 2016, Nature Reviews Urology.

Prostate cancer: Multifocal disease—independent clonal lineages in malignant nodules and even in normal tissue

C. Thoma, 2015, Nature Reviews Urology.

Prostate cancer: The complex relationships of malignant cells in lethal metastatic castration-resistant disease

C. Thoma, 2015, Nature Reviews Urology.

Prostate cancer: Postdiagnosis statin use reduces mortality

C. Thoma, 2017, Nature Reviews Urology.

CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival

C. Thoma, 2015, Nature Reviews Clinical Oncology.

Bladder cancer: IMvigor211 trial outcomes reported

C. Thoma, 2018, Nature Reviews Urology.

Personalized response prediction

C. Thoma, 2018, Nature Reviews Gastroenterology & Hepatology.

Bacteriophage virome in IBD

C. Thoma, 2018, Nature Reviews Gastroenterology & Hepatology.

Bladder cancer: Mechanisms of anti-PDL1 resistance

C. Thoma, 2018, Nature Reviews Urology.

Prostate cancer: Unravelling bias in vasectomy associations

C. Thoma, 2014, Nature Reviews Urology.

Therapy: GTPase Ral—a new tumour target

C. Thoma, 2014, Nature Reviews Urology.

Prostate cancer: PLK-1 inhibition improves abiraterone efficacy

C. Thoma, 2014, Nature Reviews Urology.

Targeting DNA repair defects in prostate cancer

C. Thoma, 2020, Nature Reviews Urology.

Bladder cancer: Noninvasive diagnosis and detection of recurrence

C. Thoma, 2016, Nature Reviews Urology.

Combining epigenetic and immune checkpoint inhibitors in bladder cancer

C. Thoma, 2019, Nature Reviews Urology.

A Christian Theology of Judaism

C. Thoma, 1980 .

Infectious disease: Once-daily, single-tablet HIV PEP promises high adherence

C. Thoma, 2015, Nature reviews. Urology.

Targeting DLL3 in neuroendocrine prostate cancer

C. Thoma, 2019, Nature Reviews Urology.

Prostate cancer: Response prediction with HSD3B1

C. Thoma, 2017, Nature Reviews Urology.

Prostate cancer: PD-L1 expression is common and indicates poor prognosis

C. Thoma, 2016, Nature Reviews Urology.

Prostate cancer: Brachyury—a biomarker for progression and prognosis?

C. Thoma, 2014, Nature Reviews Urology.

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.

T. Lawrie, R. Rabbie, C. Thoma, 2013, The Cochrane database of systematic reviews.

PD-L1 and BCG response prediction

C. Thoma, 2019, Nature Reviews Urology.

Sexual dysfunction: Shortened CCH treatment for Peyronie's disease

C. Thoma, 2017, Nature Reviews Urology.

Prostate cancer: Breaking AKR1C3-mediated enzalutamide resistance by inhibiting androgen synthesis

C. Thoma, 2015, Nature Reviews Urology.

Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: implications for ovarian cancer therapy.

D. Greaves, L. Seymour, N. Green, 2013, Virology.

Bladder cancer: Chemotherapy and checkpoint blockade

C. Thoma, 2018, Nature Reviews Urology.

Prostate cancer: Validating radiographic progression-free survival

C. Thoma, 2018, Nature Reviews Urology.

Prostate cancer: Validating early PSA response to enable improved treatment decisions

C. Thoma, 2016, Nature Reviews Urology.

Prostate cancer: Changing standard of care in hormone-sensitive disease

C. Thoma, 2016, Nature Reviews Urology.

Prostate cancer: ETS factors in the balance

C. Thoma, 2017, Nature Reviews Urology.

Prostate cancer: Radium-223 safe in combination

C. Thoma, 2016, Nature Reviews Urology.

Prostate cancer: Targeting the FGFR curbs bone metastasis

C. Thoma, 2014, Nature Reviews Urology.

Kidney cancer: S1P—a promising target in sunitinib-resistant RCC

C. Thoma, 2015, Nature Reviews Urology.

Prostate cancer: Towards effective combination of ADT and immunotherapy

C. Thoma, 2016, Nature Reviews Urology.

Kidney cancer: Combining targeted and immunotherapy

C. Thoma, 2018, Nature reviews. Urology.

Erectile dysfunction: Too much ROCK — erection block

C. Thoma, 2016, Nature Reviews Urology.

Prostate cancer: Avoiding excess confirmatory biopsies

C. Thoma, 2015, Nature Reviews Urology.

Prognostic value of serial CA 125 measurements during chemotherapy for patients with advanced ovarian cancer

A. Verbeek, L. Beex, L. Massuger, 1997 .

Prostate cancer: The genomics of localized disease

C. Thoma, 2017, Nature Reviews Urology.

Prostate cancer: Stratifying salvage radiotherapy utility

C. Thoma, 2017, Nature reviews. Urology.

Kidney cancer: Combination of HDAC inhibitor with IL-2 promising

C. Thoma, 2017, Nature Reviews Urology.

Prostate cancer: Epigenetic AR regulation

C. Thoma, 2017, Nature Reviews Urology.

Identification of common polymorphisms in the mitochondrial genome

K. Deichmann, A. Heinzmann, C. Thoma, 2003, Allergy.

PSMA PET–CT outperforms conventional imaging in high-risk prostate cancer

C. Thoma, 2020, Nature reviews. Urology.

Prostate cancer: Analysis of circulating tumour DNA could guide therapy

C. Thoma, 2014, Nature Reviews Urology.

Development: Adult Leydig cell maintenance

C. Thoma, 2016, Nature Reviews Urology.

Prostate cancer: No need to rush for men with low-risk disease

C. Thoma, 2015, Nature Reviews Urology.

Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: implications for ovarian cancer therapy.

D. Greaves, L. Seymour, N. Green, 2013, Virology.

Cerebral aneurysms: Genetic risk factors are associated with the site of intracranial aneurysm development

C. Thoma, 2014, Nature Reviews Neurology.

Clinical decision-making with AR-V7

C. Thoma, 2019, Nature Reviews Urology.

Bladder cancer: Genomics of noninvasive disease

C. Thoma, 2018, Nature Reviews Urology.

Bladder cancer: Activity and safety of avelumab in JAVELIN

C. Thoma, 2018, Nature Reviews Urology.

Urothelial carcinoma: Targeting PD-1 in advanced disease

C. Thoma, 2017, Nature Reviews Urology.

Bladder cancer: Drug sequencing in metastatic disease

C. Thoma, 2017, Nature Reviews Urology.

Infection: Uropathogenic Escherichia coli get a return TRP

C. Thoma, 2015, Nature Reviews Urology.